MCID: PLM012
MIFTS: 58

Pulmonary Sarcoidosis

Categories: Immune diseases, Respiratory diseases

Aliases & Classifications for Pulmonary Sarcoidosis

MalaCards integrated aliases for Pulmonary Sarcoidosis:

Name: Pulmonary Sarcoidosis 38 12 15
Sarcoidosis, Pulmonary 76 44 73
Sarcoidosis Pulmonary 55
Lung Sarcoidosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13406
ICD10 33 D86.0 D86.2
MeSH 44 D017565
NCIt 50 C34997
SNOMED-CT 68 24369008
UMLS 73 C0036205

Summaries for Pulmonary Sarcoidosis

MalaCards based summary : Pulmonary Sarcoidosis, also known as sarcoidosis, pulmonary, is related to interstitial lung disease and chronic beryllium disease. An important gene associated with Pulmonary Sarcoidosis is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Azathioprine and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and lymph node, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Sarcoidosis is a disease involving abnormal collections of inflammatory cells that form lumps known as... more...

Related Diseases for Pulmonary Sarcoidosis

Diseases related to Pulmonary Sarcoidosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 296)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 31.5 CCL2 CCL5 IFNG SFTPD TNF
2 chronic beryllium disease 30.0 IFNG TNF
3 pneumonia 29.9 CCL2 CCL5 SFTPD TNF
4 skin sarcoidosis 29.8 ACE TNF
5 vasculitis 29.8 CCL2 ICAM1 TNF
6 bronchiolitis obliterans 29.7 CXCR3 IFNG TNF
7 bronchiolitis 29.7 CCL5 IFNG TNF
8 crescentic glomerulonephritis 29.7 CCL2 CCR5 ICAM1
9 encephalitis 29.7 CCL2 CCL5 CCR5
10 ulcerative colitis 29.6 IFNG IL2 TNF
11 colitis 29.6 IFNG IL2 TNF
12 respiratory failure 29.5 ACE SFTPD TNF
13 pulmonary tuberculosis 29.5 IFNG IL18 IL2 TNF
14 lung disease 29.5 CCL2 CCL5 CSF2 CXCR3 SFTPD TNF
15 arthritis 29.4 CCL2 CSF2 IFNG IL18 TNF
16 lymphopenia 29.4 IFNG IL2 IL2RA
17 mycobacterium tuberculosis 1 29.3 CXCR3 IFNG IL18 TNF
18 extrinsic allergic alveolitis 29.3 CCL2 CCL5 CXCL5 CXCR3 IL18 IL2RA
19 pleurisy 29.3 CCL2 ICAM1 IFNG IL2 TNF
20 leishmaniasis 29.3 CCL2 CCR5 IFNG IL2 TNF
21 uveitis 29.3 CCL2 CXCR3 ICAM1 IFNG IL2RA TNF
22 pulmonary fibrosis, idiopathic 29.1 CCL2 CCL5 CXCL5 CXCR3 IFNG IL18
23 multiple sclerosis 28.9 CCL2 CCL5 CCR5 CXCR3 ICAM1 IFNG
24 sarcoidosis 1 28.8 ACE CCL2 CSF2 CXCR3 ICAM1 IFNG
25 psoriasis 28.7 CCL2 CCL5 CXCR3 ICAM1 IFNG IL18
26 systemic lupus erythematosus 28.3 ACE CCL2 CCL5 CCR5 CXCR3 ICAM1
27 rheumatoid arthritis 28.1 CCL2 CCL5 CSF2 CXCL5 ICAM1 IFNG
28 cardiac sarcoidosis 10.3 IFNG TNF
29 autoimmune myocarditis 10.3 IFNG TNF
30 miliary tuberculosis 10.3 IFNG TNF
31 staphylococcal toxic shock syndrome 10.3 IFNG TNF
32 mucocutaneous leishmaniasis 10.3 CCR5 TNF
33 shwartzman phenomenon 10.3 ICAM1 TNF
34 anthracosis 10.3 CCL2 TNF
35 congenital cytomegalovirus 10.3 CCL2 TNF
36 african tick-bite fever 10.3 CCL5 IFNG
37 herpes simplex virus keratitis 10.3 CCL2 ICAM1
38 ileocolitis 10.3 IL2RA TNF
39 anterior uveitis 10.3 IL2RA TNF
40 whiplash 10.3 CCL5 CCR5
41 autoimmune enteropathy 10.3 ICAM1 IL2RA
42 mucormycosis 10.2 CSF2 IFNG
43 candida glabrata 10.2 CSF2 IFNG
44 burns 10.2 CSF2 TNF
45 granulomatous dermatitis 10.2 ACE TNF
46 scorpion envenomation 10.2 CCL5 TNF
47 posterior urethral valves 10.2 ACE TNF
48 subacute cutaneous lupus erythematosus 10.2 ACE TNF
49 berylliosis 10.2 IFNG IL2
50 atherosclerosis susceptibility 10.2 CCL2 ICAM1 TNF

Graphical network of the top 20 diseases related to Pulmonary Sarcoidosis:



Diseases related to Pulmonary Sarcoidosis

Symptoms & Phenotypes for Pulmonary Sarcoidosis

GenomeRNAi Phenotypes related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 ACE ICAM1 IL18 IL2 IL2RA TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 ACE ICAM1 IL18 IL2 IL2RA TNF

MGI Mouse Phenotypes related to Pulmonary Sarcoidosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 ACE CCL5 CCR5 CSF2 CXCR3 ICAM1
2 cardiovascular system MP:0005385 10.13 ACE CCR5 CSF2 CXCR3 ICAM1 IFNG
3 immune system MP:0005387 10.13 ACE CCL2 CCL5 CCR5 CSF2 CXCR3
4 homeostasis/metabolism MP:0005376 10.11 ACE CCR5 CSF2 CXCR3 ICAM1 IFNG
5 growth/size/body region MP:0005378 10.09 ACE CSF2 ICAM1 IFNG IL18 IL2
6 digestive/alimentary MP:0005381 10 CCR5 ICAM1 IFNG IL18 IL2 IL2RA
7 mortality/aging MP:0010768 10 ACE CCR5 CSF2 CXCR3 ICAM1 IFNG
8 neoplasm MP:0002006 9.76 ACE CCR5 CSF2 CXCR3 ICAM1 IFNG
9 respiratory system MP:0005388 9.5 CSF2 CXCR3 IFNG IL2 IL2RA SFTPD
10 vision/eye MP:0005391 9.17 CCR5 ICAM1 IFNG IL18 IL2 IL2RA

Drugs & Therapeutics for Pulmonary Sarcoidosis

Drugs for Pulmonary Sarcoidosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4,Phase 2 446-86-6 2265
2
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 53-03-2 5865
4
Methylprednisolone Approved, Vet_approved Phase 4,Not Applicable 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4,Not Applicable 50-24-8 5755
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Not Applicable 302-25-0
7
Methylprednisolone hemisuccinate Approved Phase 4,Not Applicable 2921-57-5
8
Nicotine Approved Phase 4,Phase 1,Phase 2 54-11-5 942 89594
9
Acetylcholine Approved Phase 4 51-84-3 187
10
Prednisolone hemisuccinate Experimental Phase 4,Not Applicable 2920-86-7
11 beta-endorphin Phase 4
12 Hormones Phase 4,Phase 3,Not Applicable
13 Adrenocorticotropic Hormone Phase 4
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Not Applicable
15 Melanocyte-Stimulating Hormones Phase 4
16 Hormone Antagonists Phase 4,Phase 3,Not Applicable
17 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Not Applicable
18 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 glucocorticoids Phase 4,Phase 3,Not Applicable
20 Antiemetics Phase 4,Phase 3,Not Applicable
21 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
22 Anti-Inflammatory Agents Phase 4,Phase 3,Not Applicable
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Protective Agents Phase 4,Phase 2,Not Applicable
25 Neurotransmitter Agents Phase 4,Phase 1,Phase 2
26 Prednisolone acetate Phase 4,Not Applicable
27 Neuroprotective Agents Phase 4,Not Applicable
28 Immunosuppressive Agents Phase 4,Phase 2
29 Methylprednisolone acetate Phase 4,Not Applicable
30 Cholinergic Agents Phase 4,Phase 1,Phase 2
31 Central Nervous System Stimulants Phase 4,Phase 1,Phase 2
32 Nicotinic Agonists Phase 4,Phase 1,Phase 2
33
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
34
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
35
Hydroxychloroquine Approved Phase 3 118-42-3 3652
36
Mycophenolic acid Approved Phase 3 24280-93-1 446541
37
Methionine Approved, Nutraceutical Phase 2, Phase 3 63-68-3 6137
38 Carbon-11 methionine Phase 2, Phase 3
39 BB 1101 Phase 3
40
protease inhibitors Phase 3
41 HIV Protease Inhibitors Phase 3
42 Antiparasitic Agents Phase 3
43 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Antirheumatic Agents Phase 3,Phase 2
45 Antiprotozoal Agents Phase 3
46 Antimalarials Phase 3
47 Antitubercular Agents Phase 3,Phase 2,Phase 1
48 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
49 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
50
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) Unknown status NCT02188017 Phase 4 Acthar gel
2 Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) Unknown status NCT01830959 Phase 4 Roflumilast;Placebo
3 Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis Recruiting NCT03320070 Phase 4 repository corticotropin injection;Placebo
4 Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis Recruiting NCT03265405 Phase 4 Low dose prednisolone;Medium dose prednisolone
5 Study of Nicotine Patches in Patients With Sarcoidosis Suspended NCT00701207 Phase 4 nicotine patch
6 Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Unknown status NCT02824419 Phase 2, Phase 3 Methionine;DOTANOC
7 Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis Unknown status NCT01920919 Phase 3 Dexamethasone;Placebo
8 Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). Completed NCT02200146 Phase 3 Prednisone;Hydroxychloroquine + Prednisone
9 Trial for the Diagnosis of Sarcoidosis Completed NCT00872612 Phase 3
10 Mycophenolate for Pulmonary Sarcoidosis Terminated NCT00262132 Phase 3 Mycophenolate
11 Treatment of Pulmonary Sarcoidosis With Pentoxifylline Completed NCT00001877 Phase 2 Pentoxifylline
12 Atorvastatin to Treat Pulmonary Sarcoidosis Completed NCT00279708 Phase 2 Atorvastatin
13 Rituximab for Pulmonary Sarcoidosis Completed NCT00855205 Phase 2 Rituximab
14 A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis Completed NCT00955279 Phase 2 Placebo;Golimumab;Ustekinumab
15 Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis Recruiting NCT02888080 Phase 2 ACZ885;Placebo
16 Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis Recruiting NCT02024555 Phase 2 Levofloxacin;Ethambutol;Azithromycin;Rifampin;Placebo
17 Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study Recruiting NCT02265874 Phase 1, Phase 2 Habitrol;Placebo to Habitrol
18 A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis Terminated NCT01732211 Phase 2
19 Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis Terminated NCT00926627 Phase 2 bosentan;placebo
20 Safety Study of Abatacept to Treat Refractory Sarcoidosis Terminated NCT00739960 Phase 2 Abatacept
21 Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Adult Patients With Common Variable Immunodeficiency (CVID) Withdrawn NCT02789397 Phase 2 Rituximab (RTX) and Azathioprine (AZA);Placebo Administration
22 Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis Completed NCT01169038 Phase 1 levaquin; ethambutol; rifampin and azithromycin.
23 Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis Not yet recruiting NCT03793439 Phase 1 Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial;Corticosteroid;Tofacitinib 5mg [Xeljanz] 1 year open-label extension
24 Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis Terminated NCT01440192 Phase 1
25 Rehabilitation in Pulmonary Sarcoidosis: a Prospective Study Unknown status NCT01384123
26 The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis Completed NCT03336736
27 The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis Completed NCT01587001 Not Applicable Placebo
28 Antibody Response to Influenza Vaccine in Patients With Sarcoidosis Completed NCT00828828
29 Sarcoidosis-associated Pulmonary Hypertension Completed NCT01139710
30 The Occurence of Inflammation and Oxidative Stress in Lung Diseases Completed NCT00512967
31 Pathogen Specific Immunity in Patients With Sarcoidosis Completed NCT00217789
32 A Prospective Study Measuring Exhaled Nitric Oxide in Exercise-Induced Asthma Completed NCT01097954
33 Eye and Immunogenetic Features of Sarcoidosis Completed NCT00379275
34 CASPA: CArdiac Sarcoidosis in PApworth Recruiting NCT03599414
35 A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis Recruiting NCT03324503 Not Applicable Glucocorticoid (prednisone or prednisolone)
36 Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG PET/CT to Assess Lung Inflammation Recruiting NCT03312712
37 Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis Recruiting NCT01745237
38 Role of Genetic Factors in the Development of Lung Disease Recruiting NCT00001532
39 Stromal Gene Expression During Pulmonary Sarcoidosis Terminated NCT00837668
40 Pulmonary Rehabilitation in Patients With Sarcoidosis Terminated NCT02044939 Not Applicable

Search NIH Clinical Center for Pulmonary Sarcoidosis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pulmonary Sarcoidosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pulmonary Sarcoidosis:
PDA001, Placenta-derived cells for pulmonary sarcoidosis
Embryonic/Adult Cultured Cells Related to Pulmonary Sarcoidosis:
Placenta-derived cells PMIDs: 22469567

Cochrane evidence based reviews: sarcoidosis, pulmonary

Genetic Tests for Pulmonary Sarcoidosis

Anatomical Context for Pulmonary Sarcoidosis

MalaCards organs/tissues related to Pulmonary Sarcoidosis:

41
Lung, T Cells, Lymph Node, Heart, Skin, Liver, Eye

Publications for Pulmonary Sarcoidosis

Articles related to Pulmonary Sarcoidosis:

(show top 50) (show all 974)
# Title Authors Year
1
Proangiogenic and Profibrotic Markers in Pulmonary Sarcoidosis. ( 29679363 )
2018
2
Pulmonary sarcoidosis. ( 29625772 )
2018
3
The Curious Omission of Treatment as a Predictor of Pulmonary Sarcoidosis Mortality. ( 29884262 )
2018
4
Pulmonary Sarcoidosis following Etanercept Treatment for Ankylosing Spondylitis: A Case Report and Review of the Literature. ( 29610700 )
2018
5
A rare presentation of pulmonary sarcoidosis as a solitary lung mass: a case report. ( 29650028 )
2018
6
Pulmonary sarcoidosis with and without extrapulmonary involvement: a cross-sectional and observational study in China. ( 29453299 )
2018
7
Pulmonary Sarcoidosis Induced by Anti-Tumor Necrosis Factor Therapy: A Paradoxical Effect. ( 29667945 )
2018
8
Right ventricular involvement and the extent of left ventricular enhancement with magnetic resonance predict adverse outcome in pulmonary sarcoidosis. ( 28967698 )
2018
9
Prognostic significance of ventricular late potentials in patients with pulmonary sarcoidosis. ( 29857850 )
2018
10
Expression analysis of extracellular microRNA in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. ( 29956871 )
2018
11
Atypical HRCT manifestations of pulmonary sarcoidosis. ( 29124658 )
2018
12
Th17-lineage cells in pulmonary sarcoidosis and LAPfgren's syndrome: Friend or foe? ( 29310925 )
2018
13
Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis. ( 29348185 )
2018
14
Evidence for M2 macrophages in granulomas from pulmonary sarcoidosis: A new aspect of macrophage heterogeneity. ( 29107084 )
2018
15
Ocular Manifestations of Biopsy-Proven Pulmonary Sarcoidosis in Korea. ( 29785303 )
2018
16
Can pulmonary sarcoidosis trigger a progressive multifocal leukoencephalopathy? Considerations from a case series and a review of literature. ( 30455904 )
2018
17
Pulmonary Sarcoidosis in a patient with Multiple Sclerosis on daclizumab monotherapy. ( 29276998 )
2018
18
Why do people die from pulmonary sarcoidosis? ( 30004991 )
2018
19
Are CT findings of pulmonary sarcoidosis ever sufficient for a presumptive diagnosis? ( 30007852 )
2018
20
Atypical CT findings of pulmonary sarcoidosis: A case report. ( 30024519 )
2018
21
In Situ Humoral Immunity to Vimentin in HLA-DRB1*03+ Patients With Pulmonary Sarcoidosis. ( 30038611 )
2018
22
Molecular profiling of regulatory T cells in pulmonary sarcoidosis. ( 30049532 )
2018
23
Whole-exome sequencing identifies rare genetic variations in German families with pulmonary sarcoidosis. ( 30054724 )
2018
24
T. marneffei infection complications in an HIV-negative patient with pre-existing pulmonary sarcoidosis: a rare case report. ( 30097066 )
2018
25
Interleukin 33 ameliorates disturbance of regulatory T cells in pulmonary sarcoidosis. ( 30195819 )
2018
26
Relationship between CT activity score with lung function and the serum angiotensin converting enzyme in pulmonary sarcoidosis on chest HRCT. ( 30200130 )
2018
27
Reprint of: The pathology of pulmonary sarcoidosis: update. ( 30262157 )
2018
28
Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial. ( 30378090 )
2018
29
Bronchial purging: Atypical pulmonary sarcoidosis presenting with bronchorrhea. ( 30381570 )
2018
30
Quantitative image analysis using chest computed tomography in the evaluation of lymph node involvement in pulmonary sarcoidosis and tuberculosis. ( 30475907 )
2018
31
Pulmonary Sarcoidosis Presenting with Thin-walled Small Cysts. ( 28420852 )
2017
32
Repository corticotropin for Chronic Pulmonary Sarcoidosis. ( 28353116 )
2017
33
Pulmonary Sarcoidosis. ( 28750459 )
2017
34
[Analysis of an association of TNF -308G>A polymorphism with a risk for pulmonary sarcoidosis in the Russian population of the Republic of Karelia]. ( 28378732 )
2017
35
Bioinformatics analysis of gene expression profile data to screen key genes involved in pulmonary sarcoidosis. ( 27682024 )
2017
36
Pulmonary Sarcoidosis That Developed During the Treatment of a Patient With Crohn Disease by Using Infliximab. ( 28503520 )
2017
37
Gastric and pulmonary sarcoidosis complicated by hypercalcemia and acute renal failure: Case report and literature review. ( 28671172 )
2017
38
Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept. ( 28124746 )
2017
39
No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. ( 29137908 )
2017
40
Ulcerating Nodules within Tattoos Revealing Pulmonary Sarcoidosis. ( 28881429 )
2017
41
Extensively disturbance of regulatory T cells - Th17 cells balance in stage II pulmonary sarcoidosis. ( 29104468 )
2017
42
Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report. ( 29515398 )
2017
43
Living Kidney Donation From a Donor With Pulmonary Sarcoidosis: AA Case Report and Review of the Literature. ( 28583552 )
2017
44
Strategies for identifying pulmonary sarcoidosis patients at risk for severe or chronic disease. ( 28076979 )
2017
45
Pulmonary sarcoidosis mimicking tuberculosis: Importance of the galaxy sign on thoracic computed tomography. ( 28863878 )
2017
46
Pulmonary sarcoidosis: an update. ( 27766929 )
2017
47
Osteoprotegerin/sRANKL Signaling System in Pulmonary Sarcoidosis: A Bronchoalveolar Lavage Study. ( 27826889 )
2017
48
Immunology repertoire study of pulmonary sarcoidosis T cells in CD4+, CD8+ PBMC and tissue. ( 29163767 )
2017
49
Resolution rate of pulmonary sarcoidosis and its related factors in a Japanese population. ( 28712145 )
2017
50
Predictors of Mortality in Pulmonary Sarcoidosis. ( 28728933 )
2017

Variations for Pulmonary Sarcoidosis

Expression for Pulmonary Sarcoidosis

Search GEO for disease gene expression data for Pulmonary Sarcoidosis.

Pathways for Pulmonary Sarcoidosis

Pathways related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CCL2 CCL5 CCR5 CSF2 ICAM1 IFNG
2
Show member pathways
13.84 CCL2 CCL5 CCR5 CSF2 CXCL5 CXCR3
3
Show member pathways
13.63 CCL2 CCL5 CCR5 CSF2 CXCL5 CXCR3
4
Show member pathways
13.55 CCL2 CCL5 ICAM1 IFNG IL18 IL2
5
Show member pathways
13.36 CCL2 CCL5 CCR5 CSF2 CXCL5 CXCR3
6
Show member pathways
13.35 CCL2 CCL5 CCR5 CXCL5 CXCR3 ICAM1
7
Show member pathways
13.29 CCL2 CCL5 CCR5 CSF2 ICAM1 IFNG
8
Show member pathways
13.17 CCL2 CCL5 CCR5 CSF2 CXCL5 CXCR3
9
Show member pathways
13.08 CCL2 CCL5 CCR5 CSF2 ICAM1 TNF
10
Show member pathways
13.01 ACE CCL2 CCL5 IFNG IL18 IL2
11
Show member pathways
12.9 ICAM1 IFNG IL18 IL2 IL2RA TNF
12
Show member pathways
12.88 CCL2 CCL5 CCR5 CXCL5 CXCR3
13
Show member pathways
12.72 CCL2 CCL5 ICAM1 IFNG IL18 IL2
14
Show member pathways
12.67 IFNG IL18 IL2 IL2RA TNF
15
Show member pathways
12.64 IFNG IL18 IL2 IL2RA TNF
16
Show member pathways
12.63 CCL2 IFNG IL18 IL2 TNF
17 12.62 CCL2 CCL5 IFNG IL2 IL2RA TNF
18
Show member pathways
12.56 CSF2 ICAM1 IFNG IL2 TNF
19
Show member pathways
12.48 CCR5 CSF2 IFNG IL2 TNF
20 12.47 CSF2 ICAM1 IL2 IL2RA TNF
21
Show member pathways
12.44 CCR5 CSF2 IFNG IL2 IL2RA
22
Show member pathways
12.39 CCL2 CSF2 CXCL5 IFNG TNF
23
Show member pathways
12.39 CCL2 CCL5 ICAM1 IFNG IL2 TNF
24
Show member pathways
12.31 IFNG IL18 IL2 IL2RA TNF
25
Show member pathways
12.26 CCL2 CCL5 CCR5 CXCL5 CXCR3 ICAM1
26 12.15 CCL2 ICAM1 IFNG TNF
27
Show member pathways
12.11 IFNG IL18 IL2 TNF
28 12.1 CCL2 ICAM1 IFNG IL2 TNF
29
Show member pathways
12.08 CCL2 CCL5 CCR5 CXCL5 CXCR3
30
Show member pathways
12.08 CCL2 CCL5 ICAM1 IFNG IL18 IL2
31 12.07 CSF2 IFNG IL2 IL2RA TNF
32
Show member pathways
12.05 CCR5 IFNG IL18 IL2 IL2RA
33
Show member pathways
12.04 IFNG IL2 IL2RA
34 12.04 CCL2 ICAM1 IL18 TNF
35
Show member pathways
12.01 CSF2 IFNG TNF
36 11.94 CCR5 IFNG IL2 IL2RA
37 11.9 CCL2 ICAM1 TNF
38 11.89 CSF2 IL2RA TNF
39 11.89 CSF2 IFNG TNF
40 11.89 CCL2 CCL5 CSF2 CXCL5 ICAM1 TNF
41 11.88 CSF2 ICAM1 IFNG IL2
42 11.84 CSF2 IFNG IL18
43 11.82 CSF2 IFNG IL2 TNF
44
Show member pathways
11.82 CSF2 IFNG IL2 IL2RA TNF
45 11.75 CCL2 CCL5 CSF2 TNF
46
Show member pathways
11.73 IFNG IL2 IL2RA TNF
47
Show member pathways
11.69 CSF2 ICAM1 IFNG IL2 TNF
48 11.64 CXCR3 IFNG IL18 IL2 IL2RA TNF
49 11.62 CCL2 IFNG IL18 TNF
50 11.6 IFNG IL2 TNF

GO Terms for Pulmonary Sarcoidosis

Cellular components related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 ACE CCL2 CCL5 CSF2 CXCL5 IFNG
2 cell surface GO:0009986 9.65 CCR5 CXCR3 ICAM1 IL2RA TNF
3 external side of plasma membrane GO:0009897 9.43 ACE CCR5 CXCR3 ICAM1 IL2RA TNF
4 extracellular space GO:0005615 9.36 ACE CCL2 CCL5 CSF2 CXCL5 ICAM1

Biological processes related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.98 CCL2 CCL5 CCR5 CXCL5 CXCR3 IL18
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 CCL2 CCL5 ICAM1 TNF
3 cell surface receptor signaling pathway GO:0007166 9.96 CCL2 CCR5 CXCR3 IFNG IL2RA
4 cell-cell signaling GO:0007267 9.95 CCL5 CCR5 CXCL5 IL18 IL2
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.89 ICAM1 IL18 TNF
6 defense response GO:0006952 9.89 CCR5 CXCL5 TNF
7 chemotaxis GO:0006935 9.89 CCL2 CCL5 CCR5 CXCL5 CXCR3
8 cellular response to tumor necrosis factor GO:0071356 9.88 CCL2 CCL5 ICAM1
9 response to virus GO:0009615 9.87 CCL5 IFNG TNF
10 cellular response to interferon-gamma GO:0071346 9.87 CCL2 CCL5 ICAM1
11 regulation of signaling receptor activity GO:0010469 9.86 CCL2 CCL5 CSF2 CXCL5 IFNG IL18
12 neutrophil chemotaxis GO:0030593 9.85 CCL2 CCL5 CXCL5
13 cellular response to interleukin-1 GO:0071347 9.85 CCL2 CCL5 ICAM1
14 positive regulation of inflammatory response GO:0050729 9.85 IL18 IL2 TNF
15 cell chemotaxis GO:0060326 9.85 CCL2 CCL5 CCR5 CXCL5 CXCR3
16 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.84 CCL5 IL18 TNF
17 regulation of insulin secretion GO:0050796 9.83 CCL5 IFNG TNF
18 positive regulation of T cell proliferation GO:0042102 9.83 CCL5 IL2 IL2RA
19 cellular response to organic cyclic compound GO:0071407 9.83 CCL2 CCL5 IL18 TNF
20 humoral immune response GO:0006959 9.8 CCL2 IFNG TNF
21 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 CCL5 IL18 TNF
22 chemokine-mediated signaling pathway GO:0070098 9.8 CCL2 CCL5 CCR5 CXCL5 CXCR3
23 cellular response to lipopolysaccharide GO:0071222 9.8 CCL2 CCR5 CSF2 CXCL5 ICAM1 TNF
24 positive regulation of interferon-gamma production GO:0032729 9.79 IL18 IL2 TNF
25 positive regulation of nitric oxide biosynthetic process GO:0045429 9.78 ICAM1 IFNG TNF
26 lipopolysaccharide-mediated signaling pathway GO:0031663 9.78 CCL2 CCL5 IL18 TNF
27 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 CCL5 CSF2 IFNG IL18 IL2
28 protein kinase B signaling GO:0043491 9.76 CCL2 CCL5 TNF
29 MAPK cascade GO:0000165 9.76 CCL2 CCL5 CCR5 CSF2 IL18 IL2
30 positive regulation of activated T cell proliferation GO:0042104 9.74 IL18 IL2 IL2RA
31 eosinophil chemotaxis GO:0048245 9.72 CCL2 CCL5
32 positive regulation of osteoclast differentiation GO:0045672 9.71 IFNG TNF
33 positive regulation of T cell differentiation GO:0045582 9.71 IL2 IL2RA
34 regulation of regulatory T cell differentiation GO:0045589 9.71 IFNG IL2 IL2RA
35 dendritic cell chemotaxis GO:0002407 9.7 CCL5 CCR5
36 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.7 CSF2 IL18
37 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.7 IFNG TNF
38 positive regulation of interleukin-17 production GO:0032740 9.69 IL18 IL2
39 positive regulation of podosome assembly GO:0071803 9.69 CSF2 TNF
40 macrophage chemotaxis GO:0048246 9.69 CCL2 CCL5 SFTPD
41 interleukin-2-mediated signaling pathway GO:0038110 9.68 IL2 IL2RA
42 neutrophil activation GO:0042119 9.68 CCL5 IL18
43 negative regulation of lymphocyte proliferation GO:0050672 9.65 IL2 IL2RA
44 negative regulation of macrophage apoptotic process GO:2000110 9.65 CCL5 CCR5
45 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.64 ICAM1 TNF
46 positive regulation of neuroinflammatory response GO:0150078 9.64 IL18 TNF
47 positive regulation of tissue remodeling GO:0034105 9.63 IL18 IL2
48 positive regulation of interleukin-23 production GO:0032747 9.62 CSF2 IFNG
49 cytokine-mediated signaling pathway GO:0019221 9.61 CCL2 CCL5 CCR5 CSF2 ICAM1 IL18
50 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.6 IFNG TNF

Molecular functions related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 CSF2 IL2 IL2RA
2 chemokine receptor activity GO:0004950 9.26 CCR5 CXCR3
3 cytokine activity GO:0005125 9.17 CCL2 CCL5 CSF2 IFNG IL18 IL2
4 chemokine activity GO:0008009 9.13 CCL2 CCL5 CXCL5

Sources for Pulmonary Sarcoidosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....